Active Ingredient(s): Sompacitan-beco
FDA Approved: * August 28, 2020
Pharm Company: * NOVO NORDISK INC
Category: Growth Hormone Treatment

Somapacitan, sold under the brand name Sogroya, is a growth hormone medication.[5] Somapacitan is a human growth hormone analog.[2] Somapacitan-beco is produced in Escherichia coli by recombinant DNA technology.[2] The most common side effects include: back pain, joint paint, indigestion, a sleep disorder, dizziness, tonsillitis, swelling in the arms or lower legs, vomiting, adrenal insufficiency, hypertension, increase in blood creatine phospho... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Sogroya 6.7 mg/ml Subcutaneous Injection, Solution
NDC: 0169-2030
Novo Nordisk
Sogroya 3.3 mg/ml Subcutaneous Injection, Solution
NDC: 0169-2035
Novo Nordisk
Sogroya 10 mg/ml Subcutaneous Injection, Solution
NDC: 0169-2037
Novo Nordisk